Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | -2.12% | +6.41% | +10.96% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.96% | 471M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.41% | 22.28B | |
-11.90% | 22.41B | |
-5.99% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- EF Hutton Adjusts Fate Therapeutics' Price Target to $10 From $16, Keeps Buy Rating